Skip to main content

Advertisement

SpringerLink
Log in

Hesperetin alleviated glucocorticoid-induced inhibition of osteogenic differentiation of BMSCs through regulating the ERK signaling pathway

  • Original Paper
  • Published:
Medical Molecular Morphology Aims and scope Submit manuscript

Abstract

The objective of this study is to investigate the protective role of hesperetin for the glucocorticoid-induced osteoporosis (GIOP) and related mechanisms. In this study, we investigated the protective effects of hesperetin on dexamethasone (DEX)-induced osteogenic inhibition in bone marrow mesenchymal stem cells (BMSCs). The mineralization, real-time quantitative polymerase chain reaction assays (RT-qPCR), immunofluorescence and western blot were used to assess the protective effects of hesperetin in DEX-treated BMSCs during osteogenic differentiation. Our results showed that hesperetin promoted alkaline phosphatase (ALP) activity and the mineralization in DEX-treated BMSCs during osteogenic differentiation. The expression of osteogenic mRNA and proteins further confirmed the protective effect of hesperetin in DEX-treated BMSCs. Furthermore, hesperetin activated ERK signal pathway in DEX-treated BMSCs. ERK inhibitor U0126 could abolish the protective effect of hesperein in DEX-treated BMSCs. In conclusion, our study demonstrated that hesperetin alleviated glucocorticoid-induced inhibition of osteogenic differentiation through ERK signal pathway in BMSCs. It may be a potential therapeutic agent for protecting against glucocorticoid-induced osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Rizzoli R, Biver E (2015) Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol 11:98–109

    Article  CAS  Google Scholar 

  2. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton IL, Tenenhouse A, Reeve J, Silman AJ, Pols HA, Eisman JA, McCloskey EV, Mellstrom D (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893–899

    Article  Google Scholar 

  3. Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T (2017) 2017 American College of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol 69:1521–1537

    Article  Google Scholar 

  4. Maricic M (2011) Update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 37(415–431):vi

    Google Scholar 

  5. Amiche MA, Levesque LE, Gomes T, Adachi JD, Cadarette SM (2018) Effectiveness of oral bisphosphonates in reducing fracture risk among oral glucocorticoid users: three matched cohort analyses. J Bone Miner Res 33:419–429

    Article  CAS  Google Scholar 

  6. Wu L, Ling Z, Feng X, Mao C, Xu Z (2017) Herb medicines against osteoporosis: active compounds and relevant biological mechanisms. Curr Top Med Chem 17:1670–1691

    Article  CAS  Google Scholar 

  7. Wang T, Liu Q, Tjhioe W, Zhao J, Lu A, Zhang G, Tan RX, Zhou M, Xu J, Feng HT (2017) Therapeutic potential and outlook of alternative medicine for osteoporosis. Curr Drug Targets 18:1051–1068

    CAS  PubMed  Google Scholar 

  8. Xue D, Chen E, Zhang W, Gao X, Wang S, Zheng Q, Pan Z, Li H, Liu L (2017) The role of hesperetin on osteogenesis of human mesenchymal stem cells and its function in bone regeneration. Oncotarget 8:21031–21043

    Article  Google Scholar 

  9. Hsu E, Nanes M (2017) Advances in treatment of glucocorticoid-induced osteoporosis. Curr Opin Endocrinol Diabetes Obes 24:411–417

    Article  CAS  Google Scholar 

  10. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, Ralston SH, Reeve J, Russell RG, Stevenson JC, Torgerson DJ (1998) A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 244:271–292

    Article  CAS  Google Scholar 

  11. Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319–1328

    Article  CAS  Google Scholar 

  12. Whittier X, Saag KG (2016) Glucocorticoid-induced Osteoporosis. Rheum Dis Clin North Am 42:177–189

    Article  Google Scholar 

  13. Thiele S, Hannemann A, Winzer M, Baschant U, Weidner H, Nauck M, Thakker RV, Bornhauser M, Hofbauer LC, Rauner M (2019) Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans. Endocr Connect 8:923–934

    Article  CAS  Google Scholar 

  14. Gonzalez-Rodriguez E, Aubry-Rozier B, Stoll D, Lamy O (2019) Bisphosphonates as a first-line treatment for glucocorticoid-induced osteoporosis: comment on the article by Saag et al. Arthritis Rheumatol 71:1770–1771

    Article  Google Scholar 

  15. Adami G, Saag KG (2019) Glucocorticoid-induced osteoporosis update. Curr Opin Rheumatol 31:388–393

    Article  CAS  Google Scholar 

  16. Dore RK (2013) Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis. Patient Prefer Adherence 7:435–446

    Article  Google Scholar 

  17. Pereira RM, Carvalho JF, Paula AP, Zerbini C, Domiciano DS, Goncalves H, Danowski JS, Marques Neto JF, Mendonca LM, Bezerra MC, Terreri MT, Imamura M, Weingrill P, Plapler PG, Radominski S, Tourinho T, Szejnfeld VL, Andrada NC, Committee for O, Bone Metabolic Disorders of the Brazilian Society of R, Brazilian Medical A, Brazilian Association of Physical M, Rehabilitation (2012) Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Reumatol 52:580–593

    Article  Google Scholar 

  18. Preethi Soundarya S, Sanjay V, Haritha Menon A, Dhivya S, Selvamurugan N (2018) Effects of flavonoids incorporated biological macromolecules based scaffolds in bone tissue engineering. Int J Biol Macromol 110:74–87

    Article  CAS  Google Scholar 

  19. Shen CL, Chyu MC (2016) Tea flavonoids for bone health: from animals to humans. J Investig Med 64:1151–1157

    Article  Google Scholar 

  20. Yamaguchi M (2006) Regulatory mechanism of food factors in bone metabolism and prevention of osteoporosis. Yakugaku Zasshi 126:1117–1137

    Article  CAS  Google Scholar 

  21. Zhang P, Liu Y, Wang Y, Zhang M, Lv L, Zhang X, Zhou Y (2017) SIRT6 promotes osteogenic differentiation of mesenchymal stem cells through BMP signaling. Sci Rep 7:10229

    Article  Google Scholar 

  22. Murakami J, Ishii M, Suehiro F, Ishihata K, Nakamura N, Nishimura M (2017) Vascular endothelial growth factor-C induces osteogenic differentiation of human mesenchymal stem cells through the ERK and RUNX2 pathway. Biochem Biophys Res Commun 484:710–718

    Article  CAS  Google Scholar 

  23. Lund AW, Stegemann JP, Plopper GE (2009) Inhibition of ERK promotes collagen gel compaction and fibrillogenesis to amplify the osteogenesis of human mesenchymal stem cells in three-dimensional collagen I culture. Stem Cells Dev 18:331–341

    Article  CAS  Google Scholar 

  24. Liu Q, Cen L, Zhou H, Yin S, Liu G, Liu W, Cao Y, Cui L (2009) The role of the extracellular signal-related kinase signaling pathway in osteogenic differentiation of human adipose-derived stem cells and in adipogenic transition initiated by dexamethasone. Tissue Eng Part A 15:3487–3497

    Article  CAS  Google Scholar 

  25. Aimaiti A, Wahafu T, Keremu A, Yicheng L, Li C (2019) Strontium ameliorates glucocorticoid inhibition of osteogenesis via the ERK signaling pathway. Biol Trace Elem Res. https://doi.org/10.1007/s12011-12019-02009-12016

    Article  PubMed  Google Scholar 

  26. Hu H, Li Z, Lu M, Yun X, Li W, Liu C, Guo A (2018) Osteoactivin inhibits dexamethasone-induced osteoporosis through up-regulating integrin beta1 and activate ERK pathway. Biomed Pharmacother 105:66–72

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the Zhejiang Provincial Natural Science Foundation of China (No. LQ18H050005) and Hangzhou Science and Technology Bureau Fund (No.20160533B61), Public welfare projects of Zhejiang Science and Technology Department (No.2018KY613), Zhejiang Traditional Chinese Medicine Bureau Fund (No.2019ZA086).

Author information

Authors and Affiliations

  1. Department of Nephrology, Hangzhou Hospital of Traditional Chinese Medicine, Tiyuchang Road 453, Hangzhou, 310007, Zhejiang, People’s Republic of China

    Ling Liu, Jie Zheng, YaZhen Yang, Lingjuan Ni, Hongyu Chen & Dongrong Yu

  2. Department of Nephrology (Key Laboratory of Zhejiang Province, Management of Kidney Disease), Hangzhou Hospital of Traditional Chinese Medicine, Tiyuchang Road 453, Hangzhou, 310007, People’s Republic of China

    Ling Liu, Jie Zheng, YaZhen Yang, Lingjuan Ni, Hongyu Chen & Dongrong Yu

Authors
  1. Ling Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jie Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. YaZhen Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lingjuan Ni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hongyu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dongrong Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Hongyu Chen or Dongrong Yu.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, L., Zheng, J., Yang, Y. et al. Hesperetin alleviated glucocorticoid-induced inhibition of osteogenic differentiation of BMSCs through regulating the ERK signaling pathway. Med Mol Morphol 54, 1–7 (2021). https://doi.org/10.1007/s00795-020-00251-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00795-020-00251-9

Keywords

Search

Navigation